Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dosed First Patient in Cohort 3 in the ADVANCE Phase 1/2 Trial of ADVM-043 Submitted Investigational New Drug (IND) Application for ADVM-022Plans to submit an IND Application to the FDA for ADVM-053...
-
MENLO PARK, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
-- Single Intravitreal Administration of Gene Therapy ADVM-022 ProvidesLong-term Protection in Nonhuman Primate Model of Wet AMD -- MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Adverum...
-
MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
-- 13-Month Data Show Efficacy and Durability of Protein Expression following a Single Intravitreal Administration of ADVM-022 -- -- Data to be Presented in a Poster Session on May 17, 2018 at the...
-
MENLO PARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
MENLO PARK, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular...
-
-- Data Monitoring Committee Recommends Proceeding to the Second Cohort -- -- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Feb. 26, 2018 (GLOBE...